文献速递皮肤肿瘤

实体器官移植受者皮肤癌监测项目

Skin Cancer Surveillance Program for Solid Organ Transplant Recipients.
PubMed 文献 · JAMA Dermatol · 2025-01-01

结果显示移植受者皮肤癌风险为非移植受者的7.78倍(HR 7.78;95%CI 5.97-10.10),项目实施后高危和极高危组筛查率显著提高,且未增加短期医疗资源利用。

要点

  • 移植受者皮肤癌风险显著高于非移植受者(HR 7.78)。
  • KP-SUNTRAC实施后高危组筛查率提高(HR 1.98)。
  • 极高危组筛查率亦提高(HR 2.17),且医疗利用未增加。

核心结论

  • KP-SUNTRAC风险分层监测项目与移植受者皮肤癌筛查率和检出率的提高相关,且未增加短期医疗资源利用。

研究设计与样本

  • 回顾性队列研究,纳入2016年1月1日至2023年3月31日接受实体器官移植的成人患者(≥18岁),移植受者与非受者按性别、种族和民族、医疗机构1:20匹配。
  • 数据来源为Kaiser Permanente Northern California(KPNC)移植登记库,研究分为KP-SUNTRAC实施前(2016-2021)和实施后(2022-2024)两个时期,随访至2024年3月31日。

主要发现

  • 移植受者发生皮肤癌的风险为非受者的7.78倍(HR 7.78;95%CI 5.97-10.10)。
  • KP-SUNTRAC实施后,首次检出皮肤癌的风险在实施后组显著更高(HR 2.57;95%CI 1.76-3.73)。
  • 实施后期间,高危组筛查率较实施前显著提高(HR 1.98;95%CI 1.39-2.82),极高危组亦显著提高(HR 2.17;95%CI 1.21-3.86)。
  • KP-SUNTRAC实施后医疗资源利用未增加。

关键数值与推荐

  • SUNTRAC将移植受者分为低、中、高和极高四个皮肤癌风险组。
  • 主要结局包括皮肤癌筛查次数、基底细胞癌、皮肤鳞状细胞癌、皮肤黑色素瘤或Merkel细胞癌的发病率以及医疗资源利用(皮肤科和非皮肤科就诊次数及病理标本数量)。

临床怎么用

  • 对于实体器官移植受者,可采用基于SUNTRAC的风险分层监测策略,对高危和极高危患者加强皮肤癌筛查。
  • 该策略有助于提高皮肤癌的早期检出,且不增加短期医疗资源负担。

局限性

  • 本研究为回顾性队列研究,可能存在残余混杂。
  • 研究仅基于KPNC单一整合医疗系统,结果外推需谨慎。
  • 随访时间较短,长期效益尚未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Solid organ transplant (SOT) recipients are at increased risk for skin cancer due to long-term immunosuppression. However, this risk is heterogeneous across the SOT population. The Skin and Ultraviolet Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) incorporates established clinical risk factors to stratify SOT recipients into low-, medium-, high-, and very high-risk groups for posttransplant skin cancer. OBJECTIVE: To assess skin cancer risk among SOT recipients and to evaluate the impact of a modified SUNTRAC-based surveillance program on screening rates, skin cancer incidence, and health care resource utilization. DESIGN, SETTINGS, AND PARTICIPANTS: This was a retrospective cohort study of adult patients (≥18 years) who underwent SOT from January 1, 2016, to March 31, 2023. SOT recipients and nonrecipients were identified from the transplant registry of Kaiser Permanente Northern California (KPNC), an integrated health care delivery system providing care to more than 4.5 million members. SOT recipients were matched 1:20 on sex, race and ethnicity, and medical facility with nonrecipients. The study period was divided into preimplementation of the modified SUNTRAC (ie, KP-SUNTRAC) program (2016-2021) and postimplementation (2022-2024) periods. Included participants were followed up through March 31, 2024. Data were analyzed from July 2024 to June 2025. EXPOSURE: Implementation of KP-SUNTRAC risk-based skin cancer surveillance program. MAIN OUTCOMES AND MEASURES: Among SOT recipients, the number of skin cancer screenings; skin cancer incident rates for basal cell carcinoma, cutaneous squamous cell carcinoma, cutaneous melanoma, or Merkel cell carcinoma; and health care resource utilization, measured by dermatology and nondermatology encounters and pathology specimen counts. RESULTS: The analysis included 2083 SOT recipients matched with 26 199 nonrecipients and found a 7.8-fold increased risk of developing skin cancer posttransplant among the SOT recipients compared with nonrecipients (hazard ratio [HR], 7.78; 95% CI, 5.97-10.10). After KP-SUNTRAC implementation, the risk of first detected skin cancer was significantly higher in the postimplementation group (HR, 2.57; 95% CI, 1.76-3.73). During the postimplementation period, screening rates significantly improved among the high-risk (HR, 1.98; 95% CI, 1.39-2.82) and very high-risk (HR, 2.17; 95% CI, 1.21-3.86) groups compared with preimplementation. Health care utilization did not increase after KP-SUNTRAC implementation. CONCLUSIONS AND RELEVANCE: This cohort study found that KP-SUNTRAC was associated with improved skin cancer screening rates and detection among SOT recipients at higher risk of developing skin cancer, without increasing short-term health care utilization. This targeted surveillance approach supports timely diagnosis and has the potential to reduce morbidity and future health care costs.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Lee DS, Gigoyan L, Sells RE, et al. Skin Cancer Surveillance Program for Solid Organ Transplant Recipients. JAMA Dermatol. 2025. PMID: 41091513. doi:10.1001/jamadermatol.2025.3890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。